Physician profile
Edwin E Kasha
NPI 1932108503
$4,512.18
in general payments reported to CMS, 2019-2025
14 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $29.72 · 2021: $190 · 2022: $676 · 2023: $1,209 · 2024: $1,143 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.76 |
| Education | $293.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,354.00 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $851.51 | 2022-2025 | |
| Janssen Biotech, INC. | $425.54 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $406.98 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $285.78 | 2022-2025 | Sotyktu |
| Amgen INC. | $231.04 | 2022-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $189.97 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $188.95 | 2019-2025 | |
| Almirall LLC | $145.42 | 2022-2024 | Klisyri |
| Sun Pharmaceutical Industries INC. | $142.34 | 2023-2024 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $103.08 | 2019-2025 | Adbry |
| Incyte Corporation | $85.48 | 2022 | |
| Genzyme Corporation | $61.02 | 2022-2025 | |
| Dermavant Sciences, INC. | $41.07 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Kasha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.